AP1105A - 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives. - Google Patents
2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives. Download PDFInfo
- Publication number
- AP1105A AP1105A APAP/P/1999/001572A AP9901572A AP1105A AP 1105 A AP1105 A AP 1105A AP 9901572 A AP9901572 A AP 9901572A AP 1105 A AP1105 A AP 1105A
- Authority
- AP
- ARIPO
- Prior art keywords
- adenosine
- substituted
- ch2oh
- examples
- alkyl
- Prior art date
Links
- YQUJSBYIKMQCIT-UHFFFAOYSA-N 2-purin-9-yloxolane-3,4-diol Chemical class OC1C(O)COC1N1C2=NC=NC=C2N=C1 YQUJSBYIKMQCIT-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 4’-Substituted adenosine Chemical class 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 13
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 6
- 229960005305 adenosine Drugs 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WBNQTEKLVXXLQW-MATHAZKKSA-N (3s,4r,5r)-5-(6-aminopurin-9-yl)-2,2-bis(hydroxymethyl)oxolane-3,4-diol Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1OC(CO)(CO)[C@@H](O)[C@H]1O WBNQTEKLVXXLQW-MATHAZKKSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 150000003835 adenosine derivatives Chemical class 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 125000002785 azepinyl group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
- 102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
- 101150078577 Adora2b gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 239000003121 adenosine kinase inhibitor Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003290 ribose derivatives Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9626852.9A GB9626852D0 (en) | 1996-12-24 | 1996-12-24 | Chemical compounds |
| GBGB9626845.3A GB9626845D0 (en) | 1996-12-24 | 1996-12-24 | Chemical compounds |
| GBGB9626846.1A GB9626846D0 (en) | 1996-12-24 | 1996-12-24 | Chemical compounds |
| GBGB9720536.3A GB9720536D0 (en) | 1997-09-27 | 1997-09-27 | Chemical compounds |
| GBGB9722730.0A GB9722730D0 (en) | 1997-10-29 | 1997-10-29 | Chemical compounds |
| PCT/EP1997/007197 WO1998028319A1 (en) | 1996-12-24 | 1997-12-22 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9901572A0 AP9901572A0 (en) | 1999-06-30 |
| AP1105A true AP1105A (en) | 2002-09-04 |
Family
ID=27517393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1999/001572A AP1105A (en) | 1996-12-24 | 1997-12-22 | 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives. |
Country Status (36)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| AR017457A1 (es) * | 1998-02-14 | 2001-09-05 | Glaxo Group Ltd | Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| GB9813565D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813540D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| SK19542000A3 (sk) * | 1998-06-23 | 2001-09-11 | Glaxo Group Limited | 2-(purin-9-yl)-tetrahydrofurn-3,4-diolov derivty, spsob ich vroby, farmaceutick prostriedok s ich obsahom, ich pouitie a medziprodukty |
| GB9930082D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| GB0104555D0 (en) * | 2001-02-23 | 2001-04-11 | Glaxo Group Ltd | New Therapeutic method |
| WO2002072067A2 (en) * | 2001-03-12 | 2002-09-19 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
| JP2002338593A (ja) * | 2001-05-22 | 2002-11-27 | Ajinomoto Co Inc | β−Ｄ−リボフラノース誘導体又はその光学異性体の製造方法 |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| TWI346109B (en) * | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
| ES2873875T3 (es) | 2004-05-13 | 2021-11-04 | Icos Corp | Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| AR049384A1 (es) * | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| ATE462704T1 (de) | 2004-05-26 | 2010-04-15 | Inotek Pharmaceuticals Corp | Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür |
| RU2007114887A (ru) * | 2004-09-20 | 2008-10-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Производные пурина и способы их применения |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| GB0523845D0 (en) * | 2005-11-23 | 2006-01-04 | Glaxo Group Ltd | Novel salts |
| JP5203214B2 (ja) * | 2005-11-30 | 2013-06-05 | イノテック ファーマシューティカルズ コーポレイション | プリン化合物およびその使用方法 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) * | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| AU2007302263A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as P13K lipid kinase inhibitors |
| WO2008052734A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| CA2743642C (en) | 2008-11-13 | 2017-09-19 | Calistoga Pharmaceuticals, Inc. | Therapies for hematologic malignancies |
| SI2391366T1 (sl) | 2009-01-29 | 2013-01-31 | Novartis Ag | Substituirani benzimidazoli za zdravljenje astrocitomov |
| ES2548253T3 (es) * | 2009-04-20 | 2015-10-15 | Gilead Calistoga Llc | Métodos para el tratamiento de tumores sólidos |
| MX2012000817A (es) | 2009-07-21 | 2012-05-08 | Gilead Calistoga Llc | Tratamiento para desordenes del higado con inhibidores pi3k. |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| KR20120089643A (ko) | 2009-08-12 | 2012-08-13 | 노파르티스 아게 | 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도 |
| US9085560B2 (en) | 2009-08-17 | 2015-07-21 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| US20120238520A1 (en) * | 2009-12-09 | 2012-09-20 | David Lipson | Novel Medical Use |
| EA025415B1 (ru) | 2010-01-11 | 2016-12-30 | Инотек Фармасьютикалз Корпорейшн | Комбинация, набор и способ снижения внутриглазного давления |
| WO2011119969A1 (en) | 2010-03-26 | 2011-09-29 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| US9993444B2 (en) | 2011-01-10 | 2018-06-12 | Invion, Inc. | Use of beta-adrenergic inverse agonists for smoking cessation |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| CA2828219A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
| US9062045B2 (en) | 2011-09-15 | 2015-06-23 | Novartis Ag | Triazolopyridine compounds |
| US20130209543A1 (en) | 2011-11-23 | 2013-08-15 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
| HRP20171204T1 (hr) | 2012-01-26 | 2017-10-06 | Inotek Pharmaceuticals Corporation | Anhidridni polimorfi od [(2r,3s,4r,5r)-5-(6-(ciklopentilamino)-9h-purin- 9-il)-3,4-dihidroksitetrahidrofuran-2-il)]metil-nitrata i postupci njihove proizvodnje |
| MD20140100A2 (ro) | 2012-03-05 | 2015-01-31 | Gilead Calistoga Llc | Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei |
| ES2894830T3 (es) | 2012-04-03 | 2022-02-16 | Novartis Ag | Productos combinados con inhibidores de tirosina·cinasa y su uso |
| AU2013317791B2 (en) * | 2012-09-21 | 2018-05-10 | Midwestern University | Inhibitors of beta-hydrolase for treatment of cancer |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| EA201591433A1 (ru) | 2013-03-15 | 2015-12-30 | Инотек Фармасьютикалс Корпорейшн | Офтальмологические составы |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| EP3594215A1 (en) | 2013-12-20 | 2020-01-15 | Gilead Calistoga LLC | Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors |
| US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
| NZ726360A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| KR20170036037A (ko) | 2014-07-31 | 2017-03-31 | 노파르티스 아게 | 조합 요법 |
| WO2018049145A1 (en) | 2016-09-09 | 2018-03-15 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| CN112888696B (zh) | 2018-06-21 | 2024-04-16 | 德琪医疗有限公司 | 外核苷酸酶抑制剂及其使用方法 |
| AU2020294724A1 (en) * | 2019-06-20 | 2022-01-20 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2621470A1 (de) * | 1976-05-14 | 1977-12-01 | Pharma Waldhof Gmbh & Co | Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung |
| WO1994017090A1 (en) * | 1993-01-20 | 1994-08-04 | Glaxo Group Limited | 2,6-diaminopurine derivatives |
| WO1996002553A2 (en) * | 1994-07-14 | 1996-02-01 | Glaxo Group Limited | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE768925A (fr) | 1970-06-30 | 1971-11-03 | Takeda Chemical Industries Ltd | Derives d'adenosine et procede de preparation |
| DE2034785A1 (de) | 1970-07-14 | 1972-01-20 | Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof | Adenosin 5 carbonsäurederivate |
| CA1019727A (en) | 1971-03-18 | 1977-10-25 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
| BE789773A (fr) | 1971-10-08 | 1973-04-06 | Schering Ag | Adenosines n6 -substituees et leur procede de |
| US3864483A (en) | 1972-03-22 | 1975-02-04 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
| CA1082695A (en) | 1972-04-10 | 1980-07-29 | Francis E. Fischer | Process for preparing adenosine-5'-carboxamides |
| US3966917A (en) | 1974-07-30 | 1976-06-29 | Abbott Laboratories | Platelet aggregation inhibitors |
| US4167565A (en) | 1976-11-08 | 1979-09-11 | Abbott Laboratories | Adenosine-5'-carboxamides and method of use |
| AU8379182A (en) | 1981-06-04 | 1982-12-09 | Procter & Gamble Company, The | Composition of salicylates and purine derivatives |
| CA1239397A (en) | 1983-08-01 | 1988-07-19 | James A. Bristol | N.sup.6-substituted adenosines |
| DE3406533A1 (de) | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
| US4496643A (en) | 1984-03-23 | 1985-01-29 | Eastman Kodak Company | Two-component dry electrostatic developer composition containing onium charge control agent |
| JPH0655756B2 (ja) | 1984-04-18 | 1994-07-27 | ネルソン・リサ−チ・アンド・デベロツプメント・カンパニ− | 心臓血管拡張薬としてのｎ−６置換アデノシン誘導体 |
| US5310731A (en) | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
| US4663313A (en) | 1984-10-26 | 1987-05-05 | Warner-Lambert Company | N6 -tricyclic adenosines for treating hypertension |
| AU575438B2 (en) | 1984-10-26 | 1988-07-28 | Warner-Lambert Company | N6 - substituted deoxyribose analogues of adenosines |
| US4738954A (en) | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
| US4755594A (en) | 1986-01-31 | 1988-07-05 | Warner-Lambert Company | N6 -substituted adenosines |
| US5106837A (en) | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
| US4767747A (en) | 1986-08-28 | 1988-08-30 | Warner-Lambert Company | Method for treating congestive heart failure with N6 -acenaphthyl adenosine |
| AU8274187A (en) | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Heteroaromatic derivatives of adenosine |
| WO1988003147A1 (en) | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
| NL8702926A (nl) | 1986-12-15 | 1988-07-01 | Sandoz Ag | Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten. |
| PT86660B (pt) | 1987-02-04 | 1992-02-28 | Ciba Geigy Ag | Processo para a preparacao de derivados de adenosina-5'-carboxamida |
| US4968697A (en) | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
| US4962194A (en) | 1987-04-02 | 1990-10-09 | Warner-Lambert Company | Method of preparing 51,N6-disubstituted adenosines from inosines |
| US5219840A (en) | 1987-04-06 | 1993-06-15 | Sandoz Ltd. | Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives |
| LU87181A1 (fr) | 1987-04-06 | 1988-11-17 | Sandoz Sa | Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments |
| JPH0725785B2 (ja) | 1989-01-11 | 1995-03-22 | 日本臓器製薬株式会社 | アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 |
| US5506347A (en) | 1993-02-03 | 1996-04-09 | Gensia, Inc. | Lyxofuranosyl analogues of adenosine |
| US5055569A (en) | 1989-10-19 | 1991-10-08 | G. D. Searle & Co. | N-(6)-substituted adenosine compounds |
| PT95628A (pt) | 1989-10-19 | 1991-09-30 | Searle & Co | Metodo de tratamento de perturbacoes de mobilidade gastrointestinal com composto de adenosina |
| US5140015A (en) | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US5280015A (en) | 1990-09-05 | 1994-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides |
| WO1992005177A1 (en) | 1990-09-25 | 1992-04-02 | Rhone-Poulenc Rorer International (Holdings) Inc. | Compounds having antihypertensive and anti-ischemic properties |
| FR2685918B1 (fr) | 1992-01-08 | 1995-06-23 | Union Pharma Scient Appl | Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| FR2687678B1 (fr) | 1992-01-31 | 1995-03-31 | Union Pharma Scient Appl | Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| US5424297A (en) | 1992-04-27 | 1995-06-13 | University Of Virginia Alumni Patents Foundation | Adenosine dextran conjugates |
| AU4772493A (en) | 1992-07-15 | 1994-02-14 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Sulfo-derivatives of adenosine |
| AU7331094A (en) | 1993-07-13 | 1995-02-13 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | A3 adenosine receptor agonists |
| US5446046A (en) | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
| WO1995018817A1 (fr) | 1994-01-07 | 1995-07-13 | Laboratoires Upsa | Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant |
| GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
-
1997
- 1997-12-16 TW TW086118941A patent/TW528755B/zh active
- 1997-12-22 TR TR1999/01905T patent/TR199901905T2/xx unknown
- 1997-12-22 KR KR1019997005729A patent/KR20000069682A/ko not_active Ceased
- 1997-12-22 AR ARP970106111A patent/AR011044A1/es not_active Application Discontinuation
- 1997-12-22 ID IDW990575A patent/ID22271A/id unknown
- 1997-12-22 PT PT97953888T patent/PT948509E/pt unknown
- 1997-12-22 BR BR9714082-1A patent/BR9714082A/pt not_active IP Right Cessation
- 1997-12-22 GE GEAP19974870A patent/GEP20022656B/en unknown
- 1997-12-22 SK SK865-99A patent/SK86599A3/sk unknown
- 1997-12-22 EA EA199900494A patent/EA001714B1/ru not_active IP Right Cessation
- 1997-12-22 CN CN97181854A patent/CN1246124A/zh active Pending
- 1997-12-22 DK DK97953888T patent/DK0948509T3/da active
- 1997-12-22 US US09/331,526 patent/US6426337B1/en not_active Expired - Lifetime
- 1997-12-22 HU HU0000673A patent/HUP0000673A3/hu unknown
- 1997-12-22 AU AU57622/98A patent/AU733684B2/en not_active Ceased
- 1997-12-22 DE DE69716468T patent/DE69716468T2/de not_active Expired - Lifetime
- 1997-12-22 JP JP52838098A patent/JP4156035B2/ja not_active Expired - Fee Related
- 1997-12-22 CZ CZ992309A patent/CZ230999A3/cs unknown
- 1997-12-22 WO PCT/EP1997/007197 patent/WO1998028319A1/en not_active Ceased
- 1997-12-22 SI SI9730455T patent/SI0948509T1/xx unknown
- 1997-12-22 PL PL97334218A patent/PL334218A1/xx unknown
- 1997-12-22 AP APAP/P/1999/001572A patent/AP1105A/en active
- 1997-12-22 IL IL13054797A patent/IL130547A0/xx unknown
- 1997-12-22 EP EP97953888A patent/EP0948509B1/en not_active Expired - Lifetime
- 1997-12-22 YU YU29099A patent/YU29099A/sh unknown
- 1997-12-22 AT AT97953888T patent/ATE226212T1/de not_active IP Right Cessation
- 1997-12-22 EE EEP199900312A patent/EE04019B1/xx not_active IP Right Cessation
- 1997-12-22 CA CA002275271A patent/CA2275271A1/en not_active Abandoned
- 1997-12-22 NZ NZ336332A patent/NZ336332A/xx unknown
- 1997-12-22 ES ES97953888T patent/ES2186015T3/es not_active Expired - Lifetime
- 1997-12-23 CO CO97074732A patent/CO4940488A1/es unknown
- 1997-12-23 PE PE1997001160A patent/PE27499A1/es not_active Application Discontinuation
-
1999
- 1999-06-22 BG BG103518A patent/BG63310B1/bg unknown
- 1999-06-22 OA OA9900139A patent/OA11071A/en unknown
- 1999-06-22 IS IS5089A patent/IS5089A/is unknown
- 1999-06-23 NO NO19993114A patent/NO312840B1/no unknown
-
2001
- 2001-12-19 US US10/025,678 patent/US6528494B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2621470A1 (de) * | 1976-05-14 | 1977-12-01 | Pharma Waldhof Gmbh & Co | Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung |
| WO1994017090A1 (en) * | 1993-01-20 | 1994-08-04 | Glaxo Group Limited | 2,6-diaminopurine derivatives |
| WO1996002553A2 (en) * | 1994-07-14 | 1996-02-01 | Glaxo Group Limited | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1105A (en) | 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives. | |
| EP1090020B1 (en) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | |
| US5674841A (en) | Method for inhibiting growth of stem cells | |
| Foster et al. | Fever, tumor necrosis factor, and interleukin-6 in young, mature, and aged Fischer 344 rats | |
| Vermeire et al. | Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice | |
| Kobayashi et al. | Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. | |
| EP1090022B1 (en) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | |
| EP0512528B1 (en) | Pharmaceutical compositions comprising an anticytokine | |
| US4980160A (en) | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases | |
| US7427606B2 (en) | Method to reduce inflammatory response in transplanted tissue | |
| KR20010082512A (ko) | 2-(푸린-9-일)-테트라히드로푸란-3,4-디올 유도체 | |
| HUP0102454A2 (hu) | Gyulladásgátló hatású 2-(purin-9-il)-tetrahidrofurán-3,4-diol-származékok | |
| EP1090021A1 (en) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | |
| DE69902526T2 (de) | Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate | |
| WO1993011793A1 (en) | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock | |
| AU2009204084A1 (en) | Intrathecal treatment of neuropathic pain with A2AR agonists | |
| GB9216272D0 (en) | Substituted heterocycles | |
| DE69635708T2 (de) | Tetrandrin zur behandlung von augenentzündungen | |
| DE69625682T2 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| Burchfield et al. | Effects of cold stress on tumor growth | |
| FI945696A0 (fi) | Laktaamidipeptidejä, joilla on HLE:a inhiboiva aktiivisuus | |
| Coéffier et al. | Role of interleukin‐5 in enhanced migration of eosinophils from airways of immunized guinea‐pigs | |
| IE57553B1 (en) | Synergistic composition comprising gamma interferon and lymphotoxin,and its preparation | |
| ZA200007720B (en) | 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives. | |
| US3542776A (en) | Morpholinoisonicotinamides |